Physician profile
Emile Klada
NPI 1316243355
$6,237.23
in general payments reported to CMS, 2019-2025
39 companies · $696 in 2025
The $696 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,567 · 2020: $875 · 2021: $913 · 2022: $602 · 2023: $924 · 2024: $660 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,110 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,110.32 |
| Education | $170.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $813.65 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $644.56 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $614.95 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| United Therapeutics Corporation | $465.35 | 2019-2025 | Tyvaso, Remodulin, Tyvaso |
| Baxter Healthcare | $406.29 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Grifols USA, LLC | $399.27 | 2019-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $390.99 | 2019-2025 | Dupixent |
| Insmed, INC. | $280.47 | 2019-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $254.56 | 2019-2024 | Keytruda, Zerbaxa, Recarbrio |
| Genzyme Corporation | $176.48 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $164.13 | 2019-2024 | Uptravi, Opsumit |
| Mylan Specialty L.P. | $138.52 | 2019-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $133.83 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $130.94 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $122.22 | 2020-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emile Klada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.